CDKN2A and thymic carcinoma: Ten (67 %) of 15 type A thymomas and 14 (47 %) of 30 thymic carcinomas expressed p16INK4A, whereas only one (6 %) of 17 B3 thymomas was weakly p16INK4A positive.